User login
Key clinical point: Patients with NPM1-mutant acute myeloid leukemia (AML) with NPM1-mutant measurable residual disease (MRD) positivity (MRD+) at the end of intensive chemotherapy (IC) and not undergoing hematopoietic stem cell transplant (HSCT) in the first remission had variable outcomes.
Major finding: At 12 months, 15% of patients had morphological relapse, 43% had molecular failure, 30% had complete molecular remission, and 12% had European LeukemiaNet-defined molecular persistence with a low copy number (MRD+ in complete remission).
Study details: This study included 100 patients with newly diagnosed NPM1-mutant AML who received at least 2 cycles of IC and had NPM1-mutant MRD+ at the end of IC and who did not plan to undergo HSCT in the first complete remission.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported being on a speaker’s bureau and advisory boards for, receiving research funding and royalty payments from, or consulting for various pharmaceutical companies.
Source: Tiong IS et al. Blood Adv. 2021 Sep 23. doi: 10.1182/bloodadvances.2021005455.
Key clinical point: Patients with NPM1-mutant acute myeloid leukemia (AML) with NPM1-mutant measurable residual disease (MRD) positivity (MRD+) at the end of intensive chemotherapy (IC) and not undergoing hematopoietic stem cell transplant (HSCT) in the first remission had variable outcomes.
Major finding: At 12 months, 15% of patients had morphological relapse, 43% had molecular failure, 30% had complete molecular remission, and 12% had European LeukemiaNet-defined molecular persistence with a low copy number (MRD+ in complete remission).
Study details: This study included 100 patients with newly diagnosed NPM1-mutant AML who received at least 2 cycles of IC and had NPM1-mutant MRD+ at the end of IC and who did not plan to undergo HSCT in the first complete remission.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported being on a speaker’s bureau and advisory boards for, receiving research funding and royalty payments from, or consulting for various pharmaceutical companies.
Source: Tiong IS et al. Blood Adv. 2021 Sep 23. doi: 10.1182/bloodadvances.2021005455.
Key clinical point: Patients with NPM1-mutant acute myeloid leukemia (AML) with NPM1-mutant measurable residual disease (MRD) positivity (MRD+) at the end of intensive chemotherapy (IC) and not undergoing hematopoietic stem cell transplant (HSCT) in the first remission had variable outcomes.
Major finding: At 12 months, 15% of patients had morphological relapse, 43% had molecular failure, 30% had complete molecular remission, and 12% had European LeukemiaNet-defined molecular persistence with a low copy number (MRD+ in complete remission).
Study details: This study included 100 patients with newly diagnosed NPM1-mutant AML who received at least 2 cycles of IC and had NPM1-mutant MRD+ at the end of IC and who did not plan to undergo HSCT in the first complete remission.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported being on a speaker’s bureau and advisory boards for, receiving research funding and royalty payments from, or consulting for various pharmaceutical companies.
Source: Tiong IS et al. Blood Adv. 2021 Sep 23. doi: 10.1182/bloodadvances.2021005455.